CADTH recommends that Apretude should be reimbursed by public drug plans for at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, if certain conditions are met.
